Journal of Autism and Developmental Disorders

, Volume 25, Issue 6, pp 611–626 | Cite as

The effect of clozapine on self-injurious behavior

  • Ron G. Hammock
  • Stephen R. Schroeder
  • William R. Levine
Article

Abstract

Traditional neuroleptic drugs like thioridazine and haloperidol have not proven to be systematically effective with the treatment of self-injurious behavior (SIB). These drugs may be ineffective because they primarily block D2 dopamine receptors. Based on research with humans and other animals, it appears that another dopamine receptor, D1, may be responsible for mediating some SIB. Clozapine, a neuroleptic recently introduced in the United States, has proven effective in treatment of refractory cases of schizophrenia and is known to have an affinity for blocking D1 receptors. The drug was used to complete a 93-week double-blind crossover trial with a client displaying chronic SIB. Though clozapine is known to affect other neurotransmitter systems, the successful treatment of the participant is consistent with the D1 hypothesis of self-injurious behavior and suggests the possibility that clozapine could be an effective pharmacological intervention for some cases of SIB.

Keywords

United States Schizophrenia Haloperidol Clozapine School Psychology 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Alvir, J. M., Lieberman, J. A., Safferman, A. Z., Schwimmer, J. L., & Schaaf, J. A. (1993). Clozapine-induced agranulocytosis-incidence and risk factors in the United States.New England Journal of Medicine, 329, 162–167.Google Scholar
  2. Aman, M. G., Singh, N. N., Stewart, A. W., & Field, C. J. (1985). The Aberrant Behavior Checklist: A behavior rating scale for the assessment of treatment effects.American Journal of Mental Deficiency, 89, 485–491.Google Scholar
  3. Baldessarini, R. J., & Frankenburg, F. R. (1992). Clozapine—A novel antipsychotic agent.New England Journal of Medicine, 326, 746–754.Google Scholar
  4. Baumeister, A. A., Frye, G. R., & Schroeder, S. R. (1984). Neurochemical correlates of self-injurious behavior. In J. A. Mulick & B. L. Mallory (Eds.),Transitions in mental retardation: Advocacy, technology and science (pp. 207–228). Norwood, NJ: Ablex.Google Scholar
  5. Baumeister, A. A., Todd, M. E., & Sevin, J. A. (1993). Efficacy and specificity of pharmacological therapies for behavioral disorders in persons with mental retardation.Clinical Neuropharmacology, 16, 271–294.Google Scholar
  6. Borthwick, S. A., Meyers, C. E., & Eyman, R. K. (1981). Comparative adaptive and maladaptive behavior of mentally retarded clients of five residential settings in three western states. In R. H. Bruininks, C. E. Meyers, B. B. Sigford, & K. C. Larkin (Eds.),Deinstitutionalization and community adjustment of mentally retarded people (pp. 351–359). Washington, DC: American Association on Mental Deficiency.Google Scholar
  7. Breese, G. R., Baumeister, A. A., McCowan, T. J., Emerick, S., Frye, G. D., Crotty, K., & Muller, R. A. (1984a). Behavioral differences between neonatal- and adult-6-hydroxydopamine-treated rats to dopamine agonists: Relevance to neurological symptoms in clinical syndromes with reduced brain dopamine.Journal of Pharmacology and Experimental Therapeutics, 231, 343–354.Google Scholar
  8. Breese, G. R., Baumeister, A. A., McCowan, T. J., Emerick, S., Frye, C. D., & Mueller, R. A. (1984b). Neonatal-6-hydroxydopamine treatment: Model of susceptibility for self-mutilation in the Lesch-Nyhan syndrome.Pharmacology, Biochemistry and Behavior, 21, 459–461.Google Scholar
  9. Breese, G. R., Criswell, H. E., McQuade, R. O., Iorio, L. C., & Mueller, R. A. (1990). Pharmacological evaluation of SCH-12679: Evidence of anin vivo antagonism of D-1 dopamine receptors.Journal of Pharmacology and Experimental Therapeutics, 252, 558–567.Google Scholar
  10. Carr, E. G. (1977). The motivation of self-injurious behavior: A review of some hypotheses.Psychological Bulletin, 84, 800–816.Google Scholar
  11. Cataldo, M. F., & Harris, J. (1982). The biological basis for self-injury in the mentally retarded.Analysis and Intervention in Developmental Disabilities, 2, 21–39.Google Scholar
  12. Criswell, H. E., Mueller, R. A., & Breese, G. R. (1989). Clozapine antagonism of D-1 and D-2 dopamine receptor-mediated behaviors.European Journal of Pharmacology, 159, 141–147.Google Scholar
  13. Ellenbroek, B. A. (1994). The role of serotonin receptor subtypes in the behavioral effects of neuroleptic drugs: A paw test study in rats.European Journal of Neuroscience, 6, 1–8.Google Scholar
  14. Ereshefsky, L., Watanabe, M. D., & Johnson, T. K. (1989). Clozapine: An atypical antipsychotic agent.Clinical Pharmacology, 8, 691–709.Google Scholar
  15. Farde, L., Nordstrom, A. L., Wiesel, F. A., Pauli, S., Halldin, C., & Sedvall, G. (1992). Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine.Archives of General Psychiatry, 49, 538–544.Google Scholar
  16. Favell, J. E., Azrin, N. H., Baumeister, A. A., Carr, E. G., Dorsey, M. F., Forehand, R., Foxx, R. M., Lovaas, O. I. Rincover, A., Risley, T. R., Romanczyk, R. G., Russo, D. C., Schroeder, S. R., & Solnick, J. V. (1982). The treatment of self-injurious behavior.Behavior Therapy, 13, 529–554.Google Scholar
  17. Fovel, J. T., Lash, P. S., Barron, D. A., Jr., & Roberts, M. S. (1989). A survey of self-restraint, self-injury, and other maladaptive behaviors in an institutionalized retarded population.Research in Developmental Disabilities, 10, 377–382.Google Scholar
  18. Gerson, S. L. (1993). Clozapine-deciphering the risks.New England Journal of Medicine, 329, 204–205.Google Scholar
  19. Goldstein, M., Anderson, L. T., Reuben, R., & Dancis, J. (1985). Self-mutilation in Lesch-Nyhan disease is caused by dopaminergic denervation.Lancet, 1, 338–339.Google Scholar
  20. Griffin, J. C., Williams, D. E., Stark, M. T., Altmeyer, B., & Mason, M. (1984). Self-injurious behavior: A state-wide prevalence survey assessment of severe cases, and follow-up of aversive programs. In J. C. Griffin, D. E. Williams, M. T. Stark, B. K. Altmeyer, & H. K. Griffin (Eds.),Advances in the treatment of self-injurious behavior (pp. 1–25). Austin: Texas Planning Council for Developmental Disabilities.Google Scholar
  21. Gualtieri, C. T., & Schroeder, S. R. (1989). Pharmacotherapy for self-injurious behaviors: Preliminary tests of the D-1 Hypothesis.Psychopharmacology Bulletin, 25, 364–371.Google Scholar
  22. Hill, B., & Bruininks, H. (1984). Maladaptive behavior of mentally retarded individuals in residential facilities.American Journal of Mental Deficiency, 88, 380–386.Google Scholar
  23. Iwata, B. A., Dorsey, M. F., Slifer, K. J., Bauman, K. E., & Richman, G. S. (1982). Toward a functional analysis of self-injury.Analysis and Intervention in Developmental Disabilities, 2, 3–20.Google Scholar
  24. Jacobson, J. (1982). Problem behavior and psychiatric impairment within a developmentally disabled population I: Behavior severity.Applied Research in Mental Retardation, 3, 121–139.Google Scholar
  25. Jann, M. W. (1991). Clozapine.Pharmacotherapy, 11, 179–195.Google Scholar
  26. Kane, J., Honigfeld, G., Singer, J., & Meltzer, H. (1988). Clozapine for the treatment-resistant schizophrenic.Archives of General Psychiatry, 45, 789–796.Google Scholar
  27. Lesch, M., & Nyhan, W. L. (1964). A familial disorder of uric acid metabolism and central nervous system 22 function.American Journal of Medicine, 36, 561–570.Google Scholar
  28. Markowitz, P. I. (1992). Effect of fluoxetine on self-injurious behavior in the developmentally disabled: A preliminary study.Journal of Clinical Psychopharmacology, 12, 27–31.Google Scholar
  29. Mattes, J. A. (1989). Clozapine for refractory schizophrenia: An open study of 14 patients treated up to 2 years.Journal of Clinical Psychiatry, 50, 389–391.Google Scholar
  30. Nyhan, W. L., Johnson, H., Kaufman, I., & Jones, K. (1980). Serotonergic approaches to modification of behavior in the Lesch-Nyhan Syndrome.Applied Research in Mental Retardation, 1, 25–40.Google Scholar
  31. Romanczyk, R. G. (1986). Self-injurious Behavior: Conceptualization, assessment, and treatment.Advances in Learning and Behavioral Disabilities, 5, 29–56.Google Scholar
  32. Romanczyk, R. G., Kistner, J. A., & Plienis, A. (1982). Self-stimulatory and self-injurious behavior: Etiology and treatment. In J. J. Steffan & P. Karoly (Eds.),Advances in child behavior analysis and therapy (pp. 189–254). Lexington, MA: Lexington Books.Google Scholar
  33. Schroeder, S. R., Breese, G. R., & Mueller, R. A. (1990). Dopaminergic mechanisms in self-injury. In D. K. Routh & M. Wolraich (Eds.),Advances in developmental and behavioral pediatrics (pp. 181–198). London: J. Kingsley.Google Scholar
  34. Schroeder, S. R., Schroeder, C. S., Smith, B., & Dalldorf, J. (1978). Prevalence of self-injurious behaviors in a large state facility for the retarded: A three-year follow-up study.Journal of Autism and Childhood Schizophrenia, 8, 261–269.Google Scholar
  35. Sidman, M. (1960).Tactics of scientific research. New York: Basic Books.Google Scholar
  36. Singh, N. N., & Millichamp, C. J. (1985). Pharmacological treatment of self-injurious behavior in mentally retarded persons.Journal of Autism and Developmental Disorders, 15, 257–267.Google Scholar
  37. Tate, B. G., & Baroff, G. S. (1966). Aversive control of self-injurious behavior in a psychotic boy.Behavior Research and Therapy, 4, 281–287.Google Scholar
  38. Van Tol, H. H., Bunzow, J. R., Guan, H., Sunahara, R. K., Seeman, P., Niznik, H. B., & Cevelli, O. (1991). Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic clozapine.Nature, 250, 610–614.Google Scholar
  39. Van Tol, H. H., Wu, C. M., Guan, H., Ohara, K., Bunzow, J. R., Civelli, O., Kennedy, J., Seeman, P., Niznik, H. B., & Jovanovic, V. (1992). Multiple dopamine D4 receptor variants in the human population.Nature, 358, 149–152.Google Scholar
  40. Walters, E. C., Hyrwitz, T. A., Peppard, R. F., & Caine, D. P. (1989). Clozapine: An antipsychotic agent in Parkinson's disease?Clinical Neuropharmacology, 12, 83–90.Google Scholar

Copyright information

© Plenum Publishing Corporation 1995

Authors and Affiliations

  • Ron G. Hammock
    • 1
  • Stephen R. Schroeder
    • 1
  • William R. Levine
    • 1
  1. 1.University of KansasUSA

Personalised recommendations